Conolidine’s analgesic effects stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors from the central anxious procedure, conolidine modulates alternate molecular targets. A Science Developments review located that conolidine interacts While using the atypical chemokine receptor ACKR3/CXC